Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole, cabergoline, and GnRH agonist for uterine leiomyomas
IRCT20241122063802N2Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of letrozole and cabergoline in Fibromyoma (LM) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in size of leiomyomas, Change in number of leiomyomas and 2 more. Started Sep 2025; status: completed.
02
Drugs
letrozolecabergoline
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20241122063802N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241122063802N2.